Long-term follow-up of people previously treated with KYV-101 for autoimmune diseases
Follows adults treated with KYV-101 earlier to watch for delayed side effects.
Plain-language title generated from the registry record
Registry title: A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
Key facts
- Where
- Berlin, Bochum, Hamburg, and Hanover, GermanySee the 4 sites
- Phase
- Phase 2/3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people who already received at least one infusion of KYV-101 in an earlier KYV-101 trial. It follows them over time to check for late side effects.
- Age
- 18 years or older
- Sex
- Men and women
- Earlier treatment
- Must have received at least 1 infusion of KYV-101 in a previous KYV-101 parent treatment protocol
Read by machine on 12 November 2026.
Where in Germany
- Charite Universitaetsmedizin Berlin KöRBerlin, GermanyTaking people
- Katholisches Klinikum Bochum gGmbHBochum, GermanyTaking people
- Leibniz Institute Of VirologyHamburg, GermanyTaking people
- Medizinische Hochschule HannoverHanover, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Kyverna Therapeutics
- Trial code
- NCT07403188EU 2024-511198-31-00
- Record updated
- 11 February 2026
- Original description
The purpose of this long-term follow-up (LTFU) study is to collect delayed adverse events (AEs) and understand the persistence of KYV-101 (autologous CAR T cell product; gene-modified product), in participants who have been administered KYV-101 (gene-modified product; autologous CAR T cell product).Read full original descriptionShow less
A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
The purpose of this long-term follow-up (LTFU) study is to collect delayed adverse events (AEs) and understand the persistence of KYV-101 (autologous CAR T cell product; gene-modified product), in participants who have been administered KYV-101 (gene-modified product; autologous CAR T cell product).
This LTFU protocol will be open to any participant who received at least one infusion of KYV-101 in a previous Kyverna sponsored clinical trial or Investigator Initiated Trial (IIT).
Inclusion: Provided informed consent for the LTFU study; Received at least 1 infusion of KYV-101 as part of a previous KYV-101 parent treatment protocol.
Exclusion: Not applicable.